ArticleBMC endocrine disorders2026
Association between atherogenic index of plasma and MASLD in patients with type 2 diabetes: a cross-sectional study.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM). The atherogenic index of plasma (AIP), calculated as the logarithmic ratio of triglycerides to high-density lipoprotein cholesterol (HDL-C), reflects atherogenic dyslipidemia; however, its association with MASLD specifically in patients with T2DM remains insufficiently characterized.
methodsIn this retrospective cross-sectional study, 216 adults with T2DM who underwent abdominal ultrasonography between January and September 2025 were evaluated. MASLD was diagnosed based on hepatic steatosis in the presence of metabolic dysfunction. Clinical, anthropometric, and biochemical variables were recorded. Comparative analyses, receiver operating characteristic (ROC) curve analyses, and multivariable logistic regression models were performed to assess the association between AIP and MASLD and to compare its performance with other non-invasive metabolic indices.
resultsMASLD was identified in 163 patients (75.5%). Individuals with MASLD had higher body mass index (BMI), fasting glucose, triglycerides, uric acid, and AIP levels, and lower HDL cholesterol (all p < 0.01). ROC analysis demonstrated a modest discriminative ability of AIP for MASLD (AUC = 0.690, 95% CI 0.62-0.76, p < 0.001), with an optimal cutoff value of 0.068 yielding 66.9% sensitivity and 67.9% specificity. In logistic regression analyses, AIP showed a significant association with MASLD in both univariate analysis (OR 14.66, 95% CI 4.35-54.94, p < 0.001) and after adjustment for BMI and glycated hemoglobin (HbA1c) (OR 10.40, 95% CI 2.71-44.30, p < 0.001). Similarly, the triglyceride-glucose (TyG) index remained independently associated with MASLD in adjusted models (OR 2.81, 95% CI 1.54-5.43, p = 0.001), whereas Fatty liver index (FLI) and Hepatic steatosis index (HSI) were not significantly associated with MASLD.
conclusionAIP was independently associated with MASLD in patients with T2DM; however, its discriminative performance was modest and did not exceed that of its individual lipid components. Therefore, AIP should be interpreted primarily as a composite indicator of atherogenic dyslipidemia rather than a standalone diagnostic marker for MASLD. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.